Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.

PURPOSE Recent laboratory data suggest a role for BRCA1/2 in the cellular response to DNA damage. There is a paucity of clinical data, however, examining the effect of radiotherapy (RT), which causes double-strand breaks, on breast tissue from BRCA1/2 mutation carriers. Thus the goals of this study were to compare rates of radiation-associated complications, in-breast tumor recurrence, and distant relapse in women with BRCA1/2 mutations treated with breast-conserving therapy (BCT) using RT with rates observed in sporadic disease. PATIENTS AND METHODS Seventy-one women with a BRCA1/2 mutation and stage I or II breast cancer treated with BCT were matched 1:3 with 213 women with sporadic breast cancer. Conditional logistic regression models were used to compare matched cohorts for rates of complications and recurrence. RESULTS Tumors from women in the genetic cohort were associated with high histologic (P =.0004) and nuclear (P =.009) grade and negative estrogen (P=.0001) and progesterone (P=.002) receptors compared with tumors from the sporadic cohort. Using Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer toxicity scoring, there were no significant differences in acute or chronic morbidity in skin, subcutaneous tissue, lung, or bone. The 5-year actuarial overall survival, relapse-free survival, and rates of tumor control in the treated breast for the patients in the genetic cohort were 86%, 78%, and 98%, respectively, compared with 91%, 80%, and 96%, respectively, for the sporadic cohort (P = not significant). CONCLUSION There was no evidence of increased radiation sensitivity or sequelae in breast tissue heterozygous for a BRCA1/2 germline mutation compared with controls, and rates of tumor control in the breast and survival were comparable between BRCA1/2 carriers and controls at 5 years. Although additional follow-up is needed, these data may help in discussing treatment options in the management of early-stage hereditary breast cancer and should provide reassurance regarding the safety of administering RT to carriers of a germline BRCA1/2 mutation.

[1]  D. B. Berman,et al.  Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families , 1996, Nature Medicine.

[2]  P Borgen,et al.  Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. , 1999, Journal of the National Cancer Institute.

[3]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[4]  B. Hankey,et al.  A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effect of radiation therapy. , 1983, Journal of the National Cancer Institute.

[5]  R. Weichselbaum,et al.  Significance of Family History in Breast Cancer Treated with Breast Conservation Therapy , 1996 .

[6]  D J Schaid,et al.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. , 1999, The New England journal of medicine.

[7]  P. Roberson,et al.  Dose to the contralateral breast due to primary breast irradiation. , 1985, International journal of radiation oncology, biology, physics.

[8]  R. Arriagada,et al.  Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Klijn,et al.  Rapid detection of BRCA1 mutations by the protein truncation test , 1995, Nature Genetics.

[10]  M. Stratton.  Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases , 1997, The Lancet.

[11]  J. Klijn,et al.  Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.

[12]  F. Couch,et al.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.

[13]  N. Risch,et al.  Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. , 1992, American journal of epidemiology.

[14]  B. McCormick,et al.  Duct carcinoma in situ of the breast: an analysis of local control after conservation surgery and radiotherapy. , 1991, International journal of radiation oncology, biology, physics.

[15]  M N Pollak,et al.  Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women , 1997, Cancer.

[16]  F. Vicini,et al.  Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. , 1992, International journal of radiation oncology, biology, physics.

[17]  S. Hellman,et al.  The key and the lamppost. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  O. Olopade,et al.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. , 1999, Journal of the National Cancer Institute.

[19]  A. Coldman,et al.  Radiation dose and second breast cancer. , 1985, British Journal of Cancer.

[20]  C. Lewis,et al.  Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  J. Ranstam,et al.  Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Schnitt,et al.  Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. , 1988, International journal of radiation oncology, biology, physics.

[23]  W. Willett,et al.  Jewish religion and risk of breast cancer , 1996, The Lancet.

[24]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[25]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[26]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[27]  W. Thompson,et al.  The genetic attributable risk of breast and ovarian cancer , 1996, Cancer.

[28]  Yonghong Xiao,et al.  Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.

[29]  G. Eichele,et al.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 , 1997, Nature.

[30]  D. Schultz,et al.  Family History Status as a Prognostic Factor for Breast Cancer Patients Treated with Conservative Surgery and Irradiation , 1995 .

[31]  F. Vicini,et al.  Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. , 1991, International journal of radiation oncology, biology, physics.

[32]  G J Kutcher,et al.  Intensity-modulated tangential beam irradiation of the intact breast. , 1999, International journal of radiation oncology, biology, physics.

[33]  M. Strawderman,et al.  Conservative surgery and radiotherapy for early-stage breast cancer using a lung density correction: the University of Michigan experience. , 1997, International journal of radiation oncology, biology, physics.

[34]  B Fisher,et al.  Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. , 1985, The New England journal of medicine.

[35]  M. Skolnick,et al.  BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Manola,et al.  Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Anthony J. Guidi,et al.  Local recurrence after conservative surgery and radiation therapy for ductal carcinoma in situ: Possible importance of family history. , 1995, The cancer journal from Scientific American.

[38]  G M Lenoir,et al.  Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage , 1996, Cancer.

[39]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[40]  B. Haffty,et al.  Local recurrence in the conservatively treated breast cancer patient: a correlation with age and family history. , 1998, The cancer journal from Scientific American.

[41]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[42]  A. Jacobsen,et al.  Adjuvant radiotherapy and risk of contralateral breast cancer. , 1992, Journal of the National Cancer Institute.

[43]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[44]  P Okunieff,et al.  Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. , 1995, The New England journal of medicine.

[45]  B. Weber,et al.  BRCA1 and BRCA2: from molecular genetics to clinical medicine. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.